Unparalleled Expertise in Reproductive Health Therapeutics

Founded in Switzerland in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy.

ObsEva is led by a strong management team with substantial experience in successfully developing and commercializing pharmaceutical products in our target market. ObsEva’s team members include trained obstetricians and gynecologists with an in-depth understanding of patient and physician needs. Our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Latest Company Investor presentation

 
 

Work With Us

Are you ready to join an innovative biopharmaceutical company that’s advancing women’s reproductive health and pregnancy therapeutics?
Currently we have no open vacancies but you can always join our talent community below.

Our Company

Join our team

Talent Community – Commercial

Join This Community

Talent Community – Finance & Admin

Join This Community

Talent Community – R&D / Clinical Operations

Join This Community

Talent Community – Boston Office

Join This Community

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue